Home
GSKure Technology
For Investors
Publications
Contact us
Home
GSKure Technology
For Investors
Publications
Contact us
Menu
Home
GSKure Technology
For Investors
Publications
Contact us
Publications
Media
15 Nov 2016
Science Signal Podcast Hosting Dr. Eldar Finkelman
Read More
15 Nov 2016
Glycogen synthase kinase 3 inhibitors: Proof of co
Read More
April 18, 2011
Glycogen synthase kinase-3--a promising therapeutic target: Dr Hagit Eldar-Finkelman interviewed by Em Quigley. Expert Opinion therapeutic targets 2006 10: 199-201
Read More
2016 Nov
Bird Brains" Are Smart on Alzheimer's Tel Aviv University American friends
Read More
Signaling Breakthroughs of the Year/ 2017 Science Signaling 10:eamm 5681
Read More
Science Signaling Podcast for 15 November 2016: A new type of kinase inhibitor.
Read More
A Nervous System Drug-by-Design
Read More
Nervous System Drug-by-design: Formulation May Slow Parkinson's, Alzheimer's, Huntington's
Read More
Publications
15 November 2016
A unique type of GSK-3 inhibitor brings new opportunities to the clinic
Avital Licht-Murava, Rom Paz, Lilach Vaks, Limor Avrahami, Batya Plotkin, Miriam Eisenstein, Hagit Eldar-Finkelman
Open PDF
Regulation of Th1 Cells and Experimental Autoimmune Encephalomyelitis by Glycogen Synthase Kinase-3
Ele ́onore Beurel,* Oksana Kaidanovich-Beilin,† Wen-I Yeh,‡ Ling Song,* Valle Palomo,x Suzanne M. Michalek,{ James R. Woodgett,†,‖ Laurie E. Harrington,‡ Hagit Eldar-Finkelman,# Ana Martinez,x and Richard S. Jope*
Open PDF
GSK-3 inhibition: Achieving moderate efficacy with high selectivity
Limor Avrahami a , Avital Licht-Murava a , Miriam Eisenstein b , Hagit Eldar-Finkelman a,
Open PDF
Inhibition of Glycogen Synthase Kinase-3 Ameliorates -Amyloid Pathology and Restores Lysosomal Acidification and Mammalian Target of Rapamycin Activity in the Alzheimer Disease Mouse Model
Limor Avrahami‡1, Dorit Farfara§1, Maya Shaham-Kol‡ , Robert Vassar , Dan Frenkel§2, and Hagit Eldar-Finkelman‡3
Open PDF
Exploiting Substrate Recognition for Selective Inhibition of Protein Kinases
Avital Licht-Murava and Hagit Eldar-Finkelman*
Open PDF
Elucidating Substrate and Inhibitor Binding Sites on the Surface of GSK-3β and the Refinement of a Competitive Inhibitor
Avital Licht-Murava1 , Batya Plotkin1 , Miriam Eisenstein2 and Hagit Eldar-Finkelman1
Open PDF
GSK-3 inhibitors: preclinical and clinical focus on CNS
Hagit Eldar-Finkelman1* and Ana Martinez2*
Open PDF
Substrate Competitive GSK-3 Inhibitors \ strategy and Implications
Hagit Eldar-Finkelman a, ⁎, Avital Licht-Murava a , Shmuel Pietrokovski b , Miriam Eisenstein c
Open PDF
Peptide Inhibitors Targeting Protein Kinases
Hagit Eldar-Finkelman1,* and Miriam Eisenstein2,*
Open PDF
Role of glycogen synthase kinase-3β in early depressive behavior induced by mild traumatic brain injury
Moran Shapira,a Avital Licht,a Anat Milman,b Chaim G. Pick,b Esther Shohami,c and Hagit Eldar-Finkelmana,⁎
Open PDF
Identification of Novel Glycogen Synthase Kinase-3 Substrate-interacting Residues Suggests a Common Mechanism for Substrate Recognition*
Ronit Ilouz‡1, Noga Kowalsman§2, Miriam Eisenstein¶2, and Hagit Eldar-Finkelman‡3
Open PDF
Long-Term Treatment with Novel Glycogen Synthase Kinase-3 Inhibitor Improves Glucose Homeostasis in ob/ob Mice: Molecular Characterization in Liver and Muscle
Oksana Kaidanovich-Beilin and Hagit Eldar-Finkelman
Open PDF
Insulin Mimetic Action of Synthetic Phosphorylated Peptide Inhibitors of Glycogen Synthase Kinase-3
BATYA PLOTKIN, OKSANA KAIDANOVICH, ILANA TALIOR, and HAGIT ELDAR-FINKELMAN
Open PDF
Glycogen synthase kinase 3: an emerging therapeutic target
Hagit Eldar-Finkelman
Open PDF
Rapid Antidepressive-Like Activity of Specific Glycogen Synthase Kinase-3 Inhibitor and Its Effect on -Catenin in Mouse Hippocampus
Oksana Kaidanovich-Beilin, Anat Milman, Abraham Weizman, Chaim G. Pick, and Hagit Eldar-Finkelman
Open PDF